Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE)

CUSIP: 61225M102

Q1 2026 13F Holders as of 31 Mar 2026

Holder snapshot 7 signals
Share change
+21,578,262
Put/Call ratio
37%
SEC-reported price per share
$16.45
Number of holders
189
Value change
+$355,307,204
Number of buys
128
Open additional details 1 more signal available
Number of sells
59
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
84,393,162

Security key

61225M102

Report period

Q1 2026

Institutions

189

Top holders

10

Ownership snapshot

Top reported holders of GLUE - Monte Rosa Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BAKER BROS. ADVISORS LP
Disclosed value leader
BAKER BROS. ADVISORS LP
Comparable rows
15/15
Latest evidence
31 Mar 2026
13D/G 13F 3/4/5 Lead comparable stake: 10% 13D/G row: BAKER BROS. ADVISORS LP Showing 1-6 of 15 holder rows.

Quick read

BAKER BROS. ADVISORS LP leads the comparable SEC ownership view at 10%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BAKER BROS. ADVISORS LP's linked filing trail.
Comparable ownership Top 5
BAKER BROS. ADVISORS LP 10%
Dimension Capital I, L.P. 8.1%
BIOTECHNOLOGY VALUE FUND L P 6.3%
BlackRock, Inc. 6.3%
TCG Crossover GP II, LLC 5.5%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BAKER BROS. ADVISORS LP
13D/G 13F
Company
10%
$155,158,528
8,876,346 shares
+$79,195,063 31 Mar 2026
Dimension Capital I, L.P.
13D/G
Adam Goulburn
8.1%
$107,152,737
6,513,765 shares
+$13,990,895 31 Mar 2026
BIOTECHNOLOGY VALUE FUND L P
13D/G
BVF PARTNERS L P/IL
6.3%
$88,901,287
5,085,886 shares
+$21,850,000 31 Mar 2026
BlackRock, Inc.
13F 13D/G
Company
6.3%
from 13D/G
$65,560,605
4,181,161 shares
31 Dec 2025
TCG Crossover GP II, LLC
13D/G
Chen Yu
5.5%
$80,795,199
4,622,151 shares
+$3,398,916 31 Mar 2026
SUVRETTA CAPITAL MANAGEMENT, LLC
13F 13D/G
Company
5.5%
from 13D/G
$52,684,800
3,360,000 shares
31 Dec 2025
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2026

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
189
Shares
86,952,318
Rows available
189
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q1 2026 vs Q1 2026 Across Filers

Q1 2026 holders
189
Q1 2026 holders
189
Holder diff
0
Investor Q1 2026 Shares Q1 2026 Shares Share Diff Share Chg % Q1 2026 value Q1 2026 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .